{
  "date": "2026-02-02",
  "findings": [
    {
      "time": "04:00 AM",
      "category": "CMS/Medicare",
      "priority": "CRITICAL",
      "headline": "CMS 2026 Rule Fundamentally Changes Skin Substitute Reimbursement",
      "summary": "CMS finalized major changes to skin substitute payment effective Jan 1, 2026. All products now paid as 'incident-to supplies' at flat rate of $127.28/cmÂ² (previously individual biologic codes). Expected to reduce Medicare spending by ~90%. Directly impacts Q4250 and Q4347 products.",
      "sources": [
        "https://www.cms.gov/newsroom/press-releases/cms-modernizes-payment-accuracy-significantly-cuts-spending-waste",
        "https://www.appliedpolicy.com/skin-substitutes-in-medicare-trends-challenges-and-cmss-policy-response/",
        "https://www.thewca.com/blog/medicares-2026-rule-shakes-up-wound-care-payments----what-you-need-to-know"
      ],
      "action_needed": "Review impact on pricing strategy, distributor communications, and sales projections"
    },
    {
      "time": "05:00 AM",
      "category": "Wound Care Industry",
      "priority": "MEDIUM",
      "headline": "Industry Trends: Manuka Honey Products & NPWT Systems Gaining Traction",
      "summary": "Manuka honey wound care products predicted as most popular new product in 2026. Smith+Nephew launched RENASYS EDGE NPWT System (lightweight, compact) for chronic wounds in US market (April 2024). Advanced technologies include hydrofiber dressing and collagen-orc matrix products for soft tissue regeneration.",
      "sources": [
        "https://www.einpresswire.com/article/886474743/8-wound-care-trends-for-2026-the-future-of-wound-care",
        "https://hospitalnews.com/wound-care-trends-for-2026-the-future-of-wound-care/",
        "https://www.grandviewresearch.com/industry-analysis/wound-care-market"
      ],
      "action_needed": "Monitor competitor positioning; evaluate if Clear Health Pass should explore complementary product lines or partnerships"
    },
    {
      "time": "06:00 AM",
      "category": "FDA/Regulatory",
      "priority": "MEDIUM",
      "headline": "FDA Qualifies MolecuLightDX Wound Measurement as MDDT for Product Development",
      "summary": "FDA qualified MolecuLightDX wound measurement as Medical Device Development Tool (MDDT) on Jan 29, 2026. This tool will be used for evaluating new wound care products during development. Could standardize wound measurement across industry and affect how competitors validate product efficacy.",
      "sources": [
        "https://www.biospace.com/press-releases/fda-qualifies-moleculightdx-wound-measurement-as-a-medical-device-development-tool-mddt-for-evaluating-new-products-in-wound-care",
        "http://www.prnewswire.com/news-releases/fda-qualifies-moleculightdx-wound-measurement-as-a-medical-device-development-tool-mddt-for-evaluating-new-products-in-wound-care-302673289.html"
      ],
      "action_needed": "Monitor if this becomes industry standard for clinical studies; consider for Clear Health Pass product validation protocols"
    }
  ]
}
